comelofion befween Sloofamiry profeins and menal cell carcinoma Pospibility of early diagnsis and malecular targeeing therapy

本研究旨在分析S100 A10、Anneal II和脑型脂肪酸结合蛋白（B-FABP）基因在肾细胞癌（RCC）中的表达及其作为肿瘤标志物和分子靶向治疗的潜在价值。肾癌组织切片中S100 A10和Annexin If免疫组化染色见膜上有S100 A10和Annexin If的表达。然而，在正常的肾上皮细胞中，两种抗原在Bowman囊和从Henle袢通过集合管系统的小管中染色，但在近端小管中不染色，大多数RCC来自近端小管。我们决定这两种抗原不适合作为分子靶向治疗的候选者。有趣的是，S100 A10和膜联蛋白If在所有RCC切片中染色，而不管核分级和分期。这一结果使我们可以讨论，除了肿瘤的侵袭和转移，他们也有可能血管抑素。在正常肾组织切片中未检测到B-FABP，而在ACC组织切片的胞浆中有B-FABP的表达。从RCC患者中切除的癌组织而非非癌部分的肾样品表达转录本Zr B-FABP。此外，B-FABP cDNA片段以及S100 A10在正常供体或手术后RCC患者的尿液样品中未被逆转录-聚合酶链反应（RT-PCR）扩增。然而，在手术前收集的患者尿样中扩增了B-FABP cDNA。RT-PCR的最小尿样体积为500 μ L。结论：B-FABP是一种新的肾癌标志物，S100 A10也是一种有前途的肾癌标志物。本研究为肾细胞癌的免疫层析检测提供了新的试剂盒。

This study aimed to analyze expression of S100A10, anneal II and brain-type fatty acid binding protein (B-FABP) genes in renal cell carcinoma (RCC) and their potential value as tumor markers and molecular targeting therapy. Expression of each gene or protein in the tumor than that in the normal tissues was significantly increased In the tissue sections of RCC, S100A10 and annexin If were immunostained in membranes. In the normal renal epithelia, however, both antigens were stained in the Bowman's capsule and the tubules from Henle's loop through the collecting duct system, but not in the proximal tubules, from where most RCC are derived We decided that both antigens was not suitable as a candidate for molecular targeting therapy. Interestingly, S100A10 and annexin If were stained in all RCC sections regardless of nuclear grade and stage. This result allowed us to discuss that except for tumor invasion and metastasis, they also have the possibility of angiostatin. We am further required for new approachNo B-FABP was immunohistochemically detected in normal kidney sections, but it was stained in the cytoplasm of ACC tissue sections. The carcinoma tissues but not the noncancerous parts of the kidney samples resected from patients with RCC expressed the transcript Zr B-FABP. Furthermore the B-FABP cDNA fragment as well as S100A10 was not amplified by reverse transcriptase-polymerase chain reaction (RT-PCR) in the urine samples of healthy donors or patients with RCC after surgical operation. However, B-FABP cDNA was amplified in the patient's urine samples collected before surgery. The minimum urine sample volume in RT-PCR is 500 uLIn conclusion, B-FABP is a novel marker and S100A10 is also promising marker Zr RCC. We would provide the new detection kit of RCC from urine using immunochromatography.